3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
One branch of the tryptophan catabolic cascade is the kynurenine pathway, which produces neurotoxic [3-hydroxykynurenine (3-OHKY), quinolinic acid] and neuroinhibitory (kynurenic acid) compounds. Kynurenic acid acts as a competitive antagonist at the glycine site of N-methyl-d-asparate receptors at high concentrations and as a non-competitive antagonist on the α7-nicotinic acetylcholine receptor at low concentrations. Kynurenine compounds also influence cognitive functions known to be disrupted in schizophrenia. Alterations in tryptophan metabolism are therefore of potential significance for the pathophysiology of this disorder. In this paper, tryptophan metabolites were measured from plasma using high-pressure liquid chromatography coupled with electrochemical coulometric array detection, and relationships were tested between these metabolic signatures and clinical symptoms for 25 first-episode neuroleptic-naive schizophrenia patients. Blood samples were collected and clinical and neurological symptoms were rated at baseline and again at 4 wk following initiation of treatment. Level of 3-OHKY and total clinical symptom scores were correlated when patients were unmedicated and neuroleptic-naive, and this relationship differed significantly from the correlation observed for patients 4 wk after beginning treatment. Baseline psychosis symptoms were predicted only by neurological symptoms. Moreover, baseline 3-OHKY predicted clinical change at 4 wk, with the lowest concentrations of 3-OHKY being associated with the greatest improvement in symptoms. Taken together, our findings suggest a neurotoxic product of tryptophan metabolism, 3-OHKY, predicts severity of clinical symptoms during the early phase of illness and before exposure to antipsychotic drugs. Baseline level of 3-OHKY may also predict the degree of clinical improvement following brief treatment with antipsychotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982 · cited 2×
“Clinical and neurological symptoms were rated by experienced research clinicians at both time-points using standard rating scales : Brief Psychiatric Rating Scale (BPRS; Overall & Gorham, 1962), Scale for Assessment of Negative Symptoms (SANS) and Scale for Assessment of Positive Symptoms (SAPS; Andreasen, 1983 ; 1984…”
MethodThe Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693 · cited 2×
“While the dopamine hypothesis of schizophrenia has retained prominence for over four decades (Carlsson & Lindqvist, 1963 ; Howes & Kapur, 2009), progress in the field has stimulated alternate views that recognize complex relationships among multiple neurotransmitter systems and include a renewed…”
BackgroundNMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020
Increased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590
Metabolomic Mapping of Atypical Antipsychotic Effects in Schizophrenia
Kaddurah-Daouk, R., McEvoy, J., Baillie, R. A., Lee, D., Yao, J. K., Doraiswamy, P. M., & Krishnan, K. R. R. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002000 · Cited by 262 · cited 1×
“…of genetic, protein, metabolic, cellular, and pathway cascades provides a new paradigm (Clish et al. 2004) that has the potential to transform knowledge about the major psychiatric disorders, including schizophrenia and mood disorders (Kaddurah-Daouk et al. 2007, 2008, 2009 ; Yao & Reddy, 2005).”
BackgroundKynurenine pathway in psychosis: evidence of increased tryptophan degradation
Barry, S., Clarke, G., Scully, P., & Dinan, T. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108089583 · Cited by 96 · cited 2×
“Increased degradation of tryptophan through the kynurenine pathway has been observed in patients diagnosedwith psychotic disorder (Barry et al. 2009), and elevated levels of kynurenic acid have been found in cerebrospinal fluid (CSF) of schizophrenia patients at first episode and prior to treatment with antipsychotics…”
BackgroundMetabolic Investigation in Psychiatric Disorders
Yao, J. K., & Reddy, R. D. (2005) · Molecular Neurobiology · doi:10.1385/mn:31:1-3:193 · Cited by 33 · cited 1×
“…of genetic, protein, metabolic, cellular, and pathway cascades provides a new paradigm (Clish et al. 2004) that has the potential to transform knowledge about the major psychiatric disorders, including schizophrenia and mood disorders (Kaddurah-Daouk et al. 2007, 2008, 2009 ; Yao & Reddy, 2005).”
BackgroundSelf-citation
Cited by
Tryptophan metabolism in health and disease
Xue, C., Li, G., Zheng, Q., Gu, X., Shi, Q., Su, Y., Chu, Q., Yuan, X., Bao, Z., Lu, J., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.06.004 · Cited by 961
Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations.
Müller, N. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby024 · Cited by 648
The role of inflammation in schizophrenia
Müller, N., Weidinger, E., Leitner, B., & Schwarz, M. J. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00372 · Cited by 465
Developmental neuroinflammation and schizophrenia
Meyer, U. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.11.003 · Cited by 300
Kindler, J., Lim, C. K., Weickert, C. S., Boerrigter, D., Galletly, C., Liu, D., Jacobs, K. R., Balzan, R., Bruggemann, J., O’Donnell, M., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0401-9 · Cited by 284
Metadata
- Authors
- Condray, R., Dougherty, G. G., Keshavan, M. S., Reddy, R. D., Haas, G. L., Montrose, D. M., Matson, W. R., McEvoy, J., Kaddurah-Daouk, R., & Yao, J. K.
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-01-28
- Volume
- 14
- Issue
- 06
- Pages
- 756-767
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2137102585
- Cited by
- 98
- References
- 7
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. https://app.cochat.ai/papers/10.1017/s1461145710001689
- The paper
- Condray, R., Dougherty, G. G., Keshavan, M. S., Reddy, R. D., Haas, G. L., Montrose, D. M., Matson, W. R., McEvoy, J., Kaddurah-Daouk, R., & Yao, J. K. (2011). 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145710001689
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.